Skip to content

Steris PLC

US · STE #909 by market cap Listed 1970
255.76 +1.00 +0.39%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

Valuation each multiple against its own 5-year range

P/B ratio 3.42 In line with history 53rd percentile
5-year average 3.34 · #78 of 128 in Medical Devices
P/E ratio 30.38 Cheap vs history 21st percentile
5-year average -130.18 · forward 26.37 · #26 of 39 in Medical Devices
P/S ratio 4.03 In line with history 34th percentile
5-year average 4.25 · forward 3.77 · #92 of 136 in Medical Devices

Vs. peers Medical Devices

Company Market cap P/E (TTM) P/B Div yield
Steris PLC (STE) 24.84B 30.38 3.42 1.01%
Abbott Laboratories (ABT) 178.39B 38.29 3.50 2.41%
Medtronic (MDT) 127.84B 24.62 2.54 2.85%
Stryker Corp (SYK) 118.01B 33.01 5.03 1.14%
Boston Scientific (BSX) 60.85B 17.71 2.37 0.00%
Edwards Lifesciences (EW) 58.56B 57.54 5.39 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value244.00 Economic moatNarrow UncertaintyMedium Capital allocationStandard

Trading 4.6% above Morningstar's fair value estimate.

Analyst note

Steris' second-quarter constant-currency organic revenue grew 8% year over year. Adjusted EPS grew 13%, excluding tariff refunds. Management maintained full-year guidance for 6%-7% revenue growth but raised its adjusted EPS outlook to $11.35-$11.55 from $11.10-$11.30, including $0.18 of refunds.

Why it matters: The result was better than we expected. Healthcare and life sciences grew 7% and 18%, respectively, while applied sterilization technologies lagged, growing only 5% as customer destocking weighed on sales. Shares traded up over 2% from the prior day's close. We were impressed by the healthcare segment's growth. Backlog levels stand near record highs, and management said recent share gains in equipment are flowing through to consumables. However, segment margin fell 110 basis points to 24.0% on inflation, lower productivity, and long-term investments. Life sciences sales benefited from fulfilling a large order from a single customer over $10 million, roughly 6% of segment revenue, which management says will not repeat quarterly. For AST, management believes destocking has ended and noted signs of improvement in October.

The bottom line: We reaffirm our $244 fair value estimate for narrow-moat Steris and appreciated hearing more about the Xodus Medical acquisition, which was announced Oct. 12 and is expected to close by year-end. The business will likely be accretive to Steris' bottom line. The Xodus acquisition price is $1.8 billion net of tax benefits. Steris' leverage ratio was 1.2 at the end of fiscal 2026; we think the acquisition will push it up to 2.0, closer to the firm's historical leverage. Xodus is known for its Pink Pad product, a single-use positioner for hospital patients. The acquisition will likely increase Steris' presence in the operating room, but on the surface, we do not think it has a material impact on the firm's competitive advantages or moat.

Fair value

We maintain our $244 fair value estimate for narrow-moat Steris, mainly supported by mid- to high-single-digit revenue growth and slight margin expansion.

We expect the majority of top-line growth to come from the healthcare segment. Steris’ healthcare business benefits from the secular demand for medical procedures, as the aging population becomes a dominant trend across the company’s major markets. We think the increase in preventive screenings would bring strong tailwinds to products serving endoscopy suites in the long term.

Acquisitions have been a key part of Steris’ healthcare segment, but after its unsuccessful dental integration, we expect the company will become more careful when evaluating potential synergies from future transaction opportunities. We have a positive view of the firm's recently authorized share repurchase announcement and believe the smaller tuck-in acquisitions that Steris is currently pursuing serve as a defensible use of capital.

We believe AST's top-line growth will reach 10% as new plants ramp up production and forecast the segment to eclipse $1.5 billion in revenue by 2030. AST carries the highest margins and fastest revenue growth across Steris’ three segments, and the firm is nearing completion of its multiyear X-ray AST expansion that has allowed it to further its technological prowess and maintain its leading sterilization offering.

Economic moat

We think Steris has a narrow economic moat supported by high switching costs across its healthcare, life sciences, and applied sterilization technologies, or AST, businesses. As a leading provider of sterilization services and equipment, Steris has built extensive relationships with healthcare organizations, pharmaceutical companies, and medical device manufacturers. Steris’ recurring revenue sits at roughly 80% of total revenue, with most of that coming from the higher-margin services and consumables categories, which helps defend the spread between Steris’ return on invested capital and cost of capital. Moreover, we give Steris’ AST business a wide moat rating due to a more stringent regulatory environment that further strengthens customers’ switching costs.

The healthcare segment is the bread and butter of Steris’ business, currently accounting for approximately 70% of the company’s total revenue. We see a narrow moat for this segment because of Steris’ capability to generate recurring sales from consumables and services after customers make purchases of capital equipment, such as washers, sterilizers, and automated endoscope reprocessors. The capital equipment Steris sells to healthcare customers is usually priced between $20,000 $100,000 a piece, and they are a crucial part of any hospital or procedural center’s operations. Customers tend to scrutinize these instruments’ reliability, as it directly determines their operating quality and efficiency. Therefore, parts and maintenance services from the original equipment manufacturer become the preferred choice. In addition, the maintenance and sterilization cost per instrument is usually less than $1. Given the low-cost, mission-critical nature of the sterilization process, we see strong switching costs once a healthcare provider chooses to source equipment from Steris. Steris often enters into preventive maintenance and extended warranty agreements with clients for up to 5 years, and their instrument reprocessing services contracts with clients can last up to 15 years. These contract terms allow Steris to capture value throughout the capital equipment’s lifespan while keeping clients within its ecosystem, which we view as a variant of the razor-and-blade business model common in the medical devices industry.

Many companies compete with Steris in the healthcare space both product-wise and service-wise, including wide-moat Stryker and no-moat Getinge. We believe independent ambulatory surgery centers, or ASCs, and physician offices, which do not have the same procurement resources as hospitals, often find Steris’ integrated solutions more attractive than what Steris’ competitors can provide. Steris constantly seeks acquisition opportunities to enhance its healthcare offerings, and we think these transactions can grow Steris’ top line without diluting its moat.

Steris’ Applied Sterilization Technologies, or AST, segment comprises 19% of total revenue and provides contract sterilization services and sterility validation services to medical device and pharmaceutical manufacturers. We give this segment a wide moat rating because we see stronger switching costs stemming from stringent regulatory requirements. Steris provides both radiation-based and gas-based sterilization, and these processes often involve harmful materials such as Cobalt-60 and Ethylene Oxide that are known to cause cancer. Given the high risk of excessive chemical residuals, the US Food and Drug Administration requires medical device manufacturers to include sterility information in their 510(k) or premarket approval submissions. Once accepted by the FDA, a medical device manufacturer is unlikely to switch to another sterilization provider, as it usually requires supplementary filing. In addition, 80% of Steris’ AST customers are on 3-to-5-year contracts, which also helps retain high switching costs.

The only major competitor to Steris’ AST business is Sterigenics, a subsidiary of Sotera Health. Environmental backlash related to excessive ethylene oxide, or ETO, emissions have been troubling Sterigenics in recent years and the competitor has been more severely affected by material lawsuits relating to EtO’s potential toxic effects. While fiscal 2025 brought a smaller but similar problem to Steris, the monetary impacts of recent settlements are not significant to our valuation estimate. We see traces of intangible assets in Steris’ AST process that complement its switching costs, as Steris’ unique participation with the FDA’s Master File Pilot Programs on radiation and ETO sterilization highlight the firm's deep domain knowledge and make it a preferred and trusted partner.

We think Steris’ life sciences segment, which comprises approximately 10% of total revenue, enjoys a narrow moat because it follows a razor-and-blade business model similar to the healthcare segment. It also sells capital equipment, such as sterilizers and washers, and the associated consumables and maintenance services. However, instead of hospitals and procedural centers, this segment’s end market is vaccine and biopharma makers who require aseptic (contamination-free) manufacturing processes. Despite the smaller size, we consider life sciences to have a more attractive business mix than healthcare as it focuses purely on the higher margin sterilization products, whereas healthcare also sells other types of equipment used in the operating room, such as surgical lights and tables. Meanwhile, 75% of the life sciences revenue comes from consumables and services, compared with Healthcare’s roughly 70%. Thanks to the favorable mix, life sciences’ operating margin is around 18 percentage points higher than Healthcare’s, and we expect this trend to continue through our five-year explicit forecast period.

Bull case

Steris’ technological leadership in applied sterilization technologies, or AST, could attract new customers that lack the capacity to navigate regulatory challenges.

Steris’ track record of supplying mission-critical sterilization plus operating room and endoscopy equipment creates durable switching costs for healthcare providers with stable long-term growth trends.

An aging population and increased adherence to preventive screening could increase endoscopy utilization.

Bear case

Steris’ frequent acquisitions may not always achieve promised synergies, especially for businesses operating in niche verticals like dental or renal.

Innovation in sterilization and bioprocessing processes may impair the attractiveness of Steris’ current healthcare and life sciences offerings.

Uncertainty with ETO regulations may affect the expansion plans of applied sterilization technologies globally.

By Jay Lee, Robert Winebrenner

Quote time 2026-11-20 20:01:07 · For reference only, not investment advice and not tailored to your situation.

Steris PLC discussion 0 comments

Add a comment